MedTrace Logo

Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI

NCT02481440 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2020-06-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of repeated intrathecal administrations of allogeneic human umbilical cord mesenchymal stem cells for the treatment of spinal cord injury.

Conditions

  • Spinal Cord Injuries

Interventions

BIOLOGICAL

human umbilical cord mesenchymal stem cells (hUC-MSCs)

Four times of intrathecal administrations of hUC-MSCs

Sponsors & Collaborators

  • Limin Rong

    lead OTHER

Principal Investigators

  • Min Li Rong, M.D. · Third Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02481440 on ClinicalTrials.gov